| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0378 |
Hospital observation service, per hour |
1,804 |
1,600 |
$974K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,977 |
6,245 |
$609K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,323 |
3,016 |
$417K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,266 |
2,916 |
$179K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
5,930 |
4,951 |
$91K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
2,104 |
1,787 |
$15K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
56 |
12 |
$10K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
12 |
12 |
$10K |
| 93880 |
|
113 |
111 |
$7K |
| 80053 |
Comprehensive metabolic panel |
10,599 |
8,644 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
3,696 |
3,372 |
$4K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,843 |
9,018 |
$4K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,126 |
1,983 |
$4K |
| 84484 |
|
4,427 |
3,548 |
$3K |
| 93922 |
|
147 |
146 |
$3K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
414 |
390 |
$2K |
| 97161 |
|
305 |
282 |
$2K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
95 |
93 |
$2K |
| 93971 |
|
56 |
53 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
642 |
523 |
$1K |
| 71045 |
Radiologic examination, chest; single view |
1,515 |
1,366 |
$1K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
67 |
50 |
$923.08 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
644 |
589 |
$774.57 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
182 |
160 |
$652.86 |
| 81001 |
|
4,150 |
3,718 |
$572.42 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,858 |
1,354 |
$481.39 |
| 83735 |
|
6,935 |
5,391 |
$448.18 |
| 83690 |
|
2,196 |
2,023 |
$400.46 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
126 |
118 |
$380.70 |
| 73562 |
|
12 |
12 |
$314.48 |
| 83880 |
|
670 |
603 |
$293.85 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,878 |
2,940 |
$275.55 |
| 83605 |
|
218 |
158 |
$273.67 |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
16 |
16 |
$250.26 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
118 |
113 |
$230.20 |
| 84443 |
Thyroid stimulating hormone (TSH) |
119 |
114 |
$207.53 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
598 |
549 |
$189.34 |
| 85610 |
|
2,697 |
2,075 |
$180.05 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,018 |
934 |
$171.86 |
| 84703 |
|
865 |
776 |
$130.81 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
208 |
202 |
$128.82 |
| 85730 |
|
274 |
245 |
$106.91 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,500 |
2,052 |
$89.53 |
| 80061 |
Lipid panel |
119 |
117 |
$82.52 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
175 |
168 |
$81.10 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,312 |
734 |
$81.06 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,182 |
1,008 |
$61.47 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
750 |
623 |
$60.37 |
| J2704 |
Injection, propofol, 10 mg |
1,512 |
1,166 |
$55.19 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,552 |
1,351 |
$51.68 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
890 |
626 |
$49.50 |
| 72100 |
|
12 |
12 |
$43.45 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,733 |
1,486 |
$41.36 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,005 |
912 |
$29.04 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
268 |
211 |
$27.22 |
| 86850 |
|
104 |
92 |
$26.06 |
| 84100 |
|
293 |
233 |
$22.87 |
| 87186 |
|
102 |
95 |
$22.18 |
| J1644 |
Injection, heparin sodium, per 1000 units |
728 |
315 |
$15.22 |
| 85379 |
|
125 |
112 |
$11.48 |
| 86901 |
|
106 |
94 |
$8.69 |
| 86900 |
|
106 |
94 |
$8.69 |
| J2060 |
Injection, lorazepam, 2 mg |
135 |
96 |
$6.11 |
| 87081 |
|
12 |
12 |
$5.20 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
207 |
191 |
$2.71 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
50 |
40 |
$1.29 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
45 |
40 |
$0.00 |
| 82550 |
|
13 |
13 |
$0.00 |
| 87040 |
|
13 |
13 |
$0.00 |
| 94760 |
|
81 |
51 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
47 |
40 |
$0.00 |
| 85027 |
|
47 |
37 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
102 |
74 |
$0.00 |
| 87205 |
|
14 |
14 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
12 |
12 |
$0.00 |
| 87070 |
|
12 |
12 |
$0.00 |
| 87077 |
|
42 |
39 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
27 |
27 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
16 |
12 |
$0.00 |
| 80050 |
General health panel |
14 |
13 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,721 |
1,305 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
64 |
56 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
18 |
13 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
90 |
86 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
89 |
86 |
$0.00 |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
12 |
12 |
$0.00 |